New pages
From Glioblastoma Treatments
Jump to navigationJump to search
- 21:08, 8 March 2025 TTF (hist | edit) [4,217 bytes] Lazy (talk | contribs) (Created page with "{{TreatmentInfo |drug_name=Tumor Treating Fields (TTFields) |FDA_approval=Yes |used_for=Newly diagnosed and recurrent glioblastoma; malignant pleural mesothelioma |clinical_trial_phase=Approved; ongoing Phase III trials for other tumor types |clinical_trial_explanation=TTFields have undergone extensive clinical evaluation, including the EF-14 Phase III trial, which demonstrated a significant survival benefit in newly diagnosed glioblastoma patients when combined with tem...")
- 20:51, 8 March 2025 Temozolomide (hist | edit) [2,933 bytes] Lazy (talk | contribs) (Created page with "|drug_name=Temozolomide (TMZ) |FDA_approval=Yes |used_for=Glioblastoma Multiforme (GBM) |clinical_trial_phase=Approved; ongoing trials exploring new combinations |common_side_effects=Nausea, vomiting, constipation, loss of appetite, fatigue, headache, hair loss, low blood cell counts |OS_with=Median survival of 14.6 months; 2-year survival rate approximately 27% |usefulness_rating=4 |usefulness_explanation=Temozolomide is the standard chemotherapy for GBM and has been sh...") Tag: Visual edit: Switched
- 19:45, 23 February 2025 COC protocol (hist | edit) [3,149 bytes] Lazy (talk | contribs) (Created page with " {{TreatmentInfo |drug_name=COC Protocol (Care Oncology Clinic Protocol) |FDA_approval=No (Individual drugs are FDA-approved for other conditions; the combination is not FDA-approved for cancer treatment) |used_for=Adjunctive metabolic therapy for glioblastoma and other cancers |clinical_trial_phase=Clinical use with retrospective analysis; some components in clinical trials for cancer |clinical_trial_explanation=The COC Protocol is being evaluated for its impact on canc...")
